Forbes September 4, 2024
Two childhood friends, united by a shared passion for science and a chance meeting on Legacy Drive, have launched Legacy Venture Capital, a firm poised to disrupt healthcare by investing in early-stage life science companies. Combining Tiffany Pham’s business acumen and Diane Shao’s scientific expertise, they aim to bridge the gap between groundbreaking research and commercial success, leaving a lasting legacy in the fight against complex diseases.
From Legacy Drive To Healthcare VC Partners
The complex disease treatment market size is forecast to be more than $748.5 billion by 2034. Venture capital will be a significant catalyst for growth in the sector, transforming early-stage research into commercially successful life science solutions. The $30.6 billion invested in 2023, with 25% earmarked...
Today's Sponsors
Today's Sponsor